BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC
Others

BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC

MSD's Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
CompanyDrug

Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial

China's AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US
CompanyDrug

China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US

FDA Approves Merck's Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
CompanyDrug

FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma

Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
CompanyDrug

Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership
CompanyDeals

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products
CompanyDeals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Beijing Balance Medical's Renato System Gets NMPA Approval for Valve-in-Valve Therapy
CompanyMedical Device

Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy

North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine
CompanyDrug

North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine

Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss
CompanyDeals

Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss

Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth
Company

Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth

CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine
CompanyDrug

CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine